Drug Search Results
More Filters [+]

YTTRIUM-90

Alternative Names: yttrium-90, yttrium (90y) clivatuzumab tetraxetan, 90y-hpam4, hpam4, immu-107, yttrium
Latest Update: 2024-12-16
Latest Update Note: Clinical Trial Update

Product Description

Yttrium-90 microspheres are radioactive particles which are increasingly being employed for treating patients with unresectable hepatocellular carcinoma (HCC).

Mechanisms of Action: CD22 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for YTTRIUM-90

Countries in Clinic: China, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Hepatocellular Carcinoma

Phase 1: Liver Cancer|Oncology Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2021-13239

P1

Recruiting

Oncology Unspecified

2026-03-31

S6371

P3

Active, not recruiting

Hepatocellular Carcinoma

2025-12-31

NRT6003-HCC-2022

P1

Recruiting

Hepatocellular Carcinoma

2025-10-31

NCT05701488

P1

Recruiting

Liver Cancer|Hepatocellular Carcinoma

2025-10-01

Recent News Events